Edilio Borroni

List of Publications by Year
in descending order

42 papers	3,082 citations	186265 28 h-index	243625 44 g-index
45 all docs	45 docs citations	45 times ranked	3721 citing authors

#	Article	IF	Citations
1	Misfolded proteinase Kâ€“resistant hyperphosphorylated Î±-synuclein in aged transgenic mice with locomotor deterioration and in human Î±-synucleinopathies. Journal of Clinical Investigation, 2002, 110, 1429-1439.	8.2	292
2	Trace Amine-Associated Receptor 1 Modulates Dopaminergic Activity. Journal of Pharmacology and Experimental Therapeutics, 2008, 324, 948-956.	2.5	288
3	Effect of Bitopertin, a Glycine Reuptake Inhibitor, on Negative Symptoms of Schizophrenia. JAMA Psychiatry, 2014, 71, 637.	11.0	185
4	Age-dependent cognitive decline and amygdala pathology in Î±-synuclein transgenic mice. Neurobiology of Aging, 2007, 28, 1421-1435.	3.1	154
5	Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease. JAMA Neurology, 2021, 78, 961.	9.0	148
6	RO4938581, a novel cognitive enhancer acting at GABAA Î±5 subunit-containing receptors. Psychopharmacology, 2009, 202, 207-223.	3.1	142
7	Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders. JAMA Neurology, 2020, 77, 955.	9.0	136
8	Selective GlyT1 Inhibitors: Discovery of [4-(3-Fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methano (RG1678), a Promising Novel Medicine To Treat Schizophrenia. Journal of Medicinal Chemistry, 2010, 53, 4603-4614.	6.4	134
9	Glycine reuptake inhibitor RG1678: A pharmacologic characterization of an investigational agent for the treatment of schizophrenia. Neuropharmacology, 2012, 62, 1152-1161.	4.1	122
10	Dual Hypocretin Receptor Antagonism Is More Effective for Sleep Promotion than Antagonism of Either Receptor Alone. PLoS ONE, 2012, 7, e39131.	2.5	107
11	Pharmacology of Basimglurant (RO4917523, RG7090), a Unique Metabotropic Glutamate Receptor 5 Negative Allosteric Modulator in Clinical Development for Depression. Journal of Pharmacology and Experimental Therapeutics, 2015, 353, 213-233.	2.5	90
12	Characterization of 3 Novel Tau Radiopharmaceuticals, ¹¹C-RO-963, ¹¹C-RO-643, and ¹⁸F-RO-948, in Healthy Controls and in Alzheimer Subjects. Journal of Nuclear Medicine, 2018, 59, 1869-1876.	5.0	81
13	Identification of Three Novel Radiotracers for Imaging Aggregated Tau in Alzheimerâ€™s Disease with Positron Emission Tomography. Journal of Medicinal Chemistry, 2017, 60, 7350-7370.	6.4	74
14	Sembragiline: A Novel, Selective Monoamine Oxidase Type B Inhibitor for the Treatment of Alzheimerâ€™s Disease. Journal of Pharmacology and Experimental Therapeutics, 2017, 362, 413-423.	2.5	72
15	Preclinical Evaluation of ¹⁸F-RO6958948, ¹¹C-RO6931643, and ¹¹C-RO6924963 as Novel PET Radiotracers for Imaging Tau Aggregates in Alzheimer Disease. Journal of Nuclear Medicine, 2018, 59, 675-681.	5.0	71
16	Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease. JAMA Neurology, 2022, 79, 149.	9.0	66
17	Structure-Based Design, Synthesis, and in vitro Evaluation of Bisubstrate Inhibitors for CatecholO-Methyltransferase (COMT). Chemistry - A European Journal, 2000, 6, 971-982.	3.3	65
18	Evaluation of ¹⁸F-RO-948 PET for Quantitative Assessment of Tau Accumulation in the Human Brain. Journal of Nuclear Medicine, 2018, 59, 1877-1884.	5.0	64

#	Article	IF	Citations
19	X-ray Crystal Structure of a Bisubstrate Inhibitor Bound to the Enzyme Catechol-O-methyltransferase: A Dramatic Effect of Inhibitor Preorganization on Binding Affinity We thank F. Hoffmannâ€“La Roche for generous support of this work. We are grateful to P. Malherbe for the cloning of COMT, P. Caspers for the expression of COMT, A. Cesura for enzyme purification, B. Wipf for fermentation, and H. W. Lahm for sequencing.. Angewandte Chemie - International Edition, 2001, 40, 4040.	13.8	62
20	Application of cross-species PET imaging to assess neurotransmitter release in brain. Psychopharmacology, 2015, 232, 4129-4157.	3.1	61
21	Kinetic Modeling of the Tau PET Tracer ¹⁸F-AV-1451 in Human Healthy Volunteers and Alzheimer Disease Subjects. Journal of Nuclear Medicine, 2017, 58, 1124-1131.	5.0	60
22	Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators: Discovery of 2-Chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]pyridine (Basimglurant,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 58, 1358-1371.	6.4	58
23	Bisubstrate inhibitors for the enzyme catechol-O-methyltransferase (COMT): influence of inhibitor preorganisation and linker length between the two substrate moieties on binding affinity. Organic and Biomolecular Chemistry, 2003, 1, 42-49.	2.8	52
24	Molecular Recognition at the Active Site of Catecholâ€Oâ€Methyltransferase: Energetically Favorable Replacement of a Water Molecule Imported by a Bisubstrate Inhibitor. Angewandte Chemie - International Edition, 2009, 48, 9092-9096.	13.8	39
25	Putative Cholinergicâ€Specific Gangliosides in Guinea Pig Forebrain. Journal of Neurochemistry, 1986, 46, 1888-1894.	3.9	35
26	Molecular Recognition at the Active Site of Catecholâ€Oâ€methyltransferase (COMT): Adenine Replacements in Bisubstrate Inhibitors. Chemistry - A European Journal, 2011, 17, 6369-6381.	3.3	35
27	Sembragiline in Moderate Alzheimerâ€™s Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD). Journal of Alzheimer's Disease, 2017, 58, 1217-1228.	2.6	33
28	Bisubstrate Inhibitors of the Enzyme Catechol O-Methyltransferase (COMT): Efficient Inhibition Despite the Lack of a Nitro Group. ChemBioChem, 2004, 5, 1270-1274.	2.6	29
29	Bisubstrate Inhibitors of CatecholO-Methyltransferase (COMT): the Crucial Role of the Ribose Structural Unit for Inhibitor Binding Affinity. ChemMedChem, 2006, 1, 340-357.	3.2	29
30	The impact of demographic, clinical, genetic, and imaging variables on tau PET status. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2245-2258.	6.4	27
31	Cholinergic Surface Antigen Chol-1 Is Present in a Subclass of VIP-Containing Rat Cortical Synaptosomes. Journal of Neurochemistry, 1988, 50, 1659-1662.	3.9	26
32	Characterization of [11C]RO5013853, a novel PET tracer for the glycine transporter type 1 (GlyT1) in humans. NeuroImage, 2013, 75, 282-290.	4.2	26
33	Discovery of benzoylpiperazines as a novel class of potent and selective GlyT1 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 5134-5139.	2.2	25
34	Label-free assay for the assessment of nonspecific binding of positron emission tomography tracer candidates. European Journal of Pharmaceutical Sciences, 2015, 79, 27-35.	4.0	25
35	The developmental expression of the cholinergic-specific antigen Chol-1 in the central and peripheral nervous system of the rat. Developmental Brain Research, 1990, 52, 131-140.	1.7	24
36	Bisubstrate Inhibitors for the Enzyme Catechol O-Methyltransferase (COMT): Dramatic Effects of Ribose Modifications on Binding Affinity and Binding Mode. Helvetica Chimica Acta, 2003, 86, 1045-1062.	1.6	18

#	Article	IF	Citations
37	Discovery of benzoylisoindolines as a novel class of potent, selective and orally active GlyT1 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 6960-6965.	2.2	17
38	Further studies on the gangliosidic nature of the cholinergic-specific antigen, Chol-1. Archives of Biochemistry and Biophysics, 1990, 280, 211-216.	3.0	16
39	Synthesis and Biological Evaluation of Potent Bisubstrate Inhibitors of the Enzyme CatecholO-Methyltransferase (COMT) Lacking a Nitro Group. Helvetica Chimica Acta, 2006, 89, 1856-1887.	1.6	16
40	Pre-clinical characterization of [11C]R05013853 as a novel radiotracer for imaging of the glycine transporter type 1 by positron emission tomography. NeuroImage, 2013, 75, 291-300.	4.2	16
41	P4â€185: First inâ€human PET study of 3 novel tau radiopharmaceuticals: [¹¹C]RO6924963, [¹¹C]RO6931643, and [¹⁸F]RO6958948. Alzheimer's and Dementia, 2015, 11, P850.	0.8	12
42	[ICâ€Pâ€188]: ON EVALUATION OF TAU ACCUMULATIONS IN LONGITUDINAL STUDIES OF ALZHEIMER's DISEASE (AD): IMPLICATIONS FROM A PET STUDY WITH [18F]RO6958948. Alzheimer's and Dementia, 2017, 13, P139.	0.8	5